+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neurodegenerative Drugs Market by Type, Drug Class, Mode Of Administration, Mechanism Of Action, Therapeutic Approach, Indication, Patient Demographics, Sales Channel, End User - Global Forecast 2025-2030- Product Image
Neurodegenerative Drugs Market by Type, Drug Class, Mode Of Administration, Mechanism Of Action, Therapeutic Approach, Indication, Patient Demographics, Sales Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Neurodegenerative Drugs Market by Type, Drug Class, Mode Of Administration, Mechanism Of Action, Therapeutic Approach, Indication, Patient Demographics, Sales Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 183 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888919
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior decision-makers navigating the neurodegenerative drugs sector face unprecedented complexity driven by scientific innovation, regulatory change, and global demographic pressures. Staying ahead requires deep insight into evolving therapeutic approaches, competition dynamics, regulatory considerations, and region-specific market shifts.

Market Snapshot: Neurodegenerative Drugs Market Overview

The Neurodegenerative Drugs Market grew from USD 44.49 billion in 2024 to USD 47.79 billion in 2025. This market is on track to sustain a CAGR of 7.66%, with projections pointing to a value of USD 69.30 billion by 2030. These growth trends reflect expanding patient populations, advancement in scientific research, and increasingly supportive regulatory environments fueling market expansion for neurodegenerative therapeutics.

Scope & Segmentation

This report delivers strategic clarity to stakeholders by analyzing a comprehensive range of product, technology, and regional segments shaping the Neurodegenerative Drugs Market.

  • Drug Types: Branded, Generics
  • Drug Classes: Cholinesterase Inhibitors (Donepezil, Pyridostigmine, Rivastigmine), Decarboxylase Inhibitors (Benserazide, Carbidopa, Methyldopa), Dopamine Agonists (Apomorphine, Cabergoline, Pramipexole, Rotigotine), Immunomodulators
  • Modes of Administration: Injectable, Oral, Transdermal Patch
  • Mechanisms of Action: Ion Channel Modulators (Potassium and Sodium Channel Modulators), Synaptic Modulators
  • Therapeutic Approaches: Neuroprotection (Anti-Inflammatory Agents, Antioxidants), Preventive Treatment, Symptomatic Treatment
  • Indications: Alzheimer’s Disease, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (Primary Progressive, Relapsing-Remitting), Parkinson’s Disease
  • Patient Demographics: Adult, Geriatric, Pediatric
  • Sales Channels: Offline (Hospital Pharmacies, Retail Pharmacies), Online
  • End Users: Clinics, Contract Research Organizations, Hospitals, Research Institutes
  • Regions Covered: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (multiple countries including United Kingdom, Germany, France, United Arab Emirates, South Africa), Asia-Pacific (China, India, Japan, Australia, and others)
  • Companies Profiled: Includes Abbott Laboratories, Biogen Inc., Pfizer, Sanofi SA, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, and over 20 other market leaders and emerging innovators.

Key Takeaways

  • Both branded and generic neurodegenerative drugs play critical roles, supporting innovation while broadening patient access worldwide.
  • New molecular targets and delivery technologies are reshaping therapeutic strategies and accelerating clinical timelines.
  • Collaboration among pharmaceutical firms, contract research organizations, and academic centers is intensifying, resulting in swift advancement from discovery to market entry.
  • Regulatory flexibility and increased real-world evidence generation are enabling faster approval and adoption, especially for therapies addressing high unmet needs.
  • Digitally-enabled patient engagement platforms and outcome-based contracting are gaining ground, setting new standards for value measurement and therapy monitoring.
  • Understanding regional regulatory frameworks and reimbursement incentives is crucial for optimizing go-to-market models and maintaining competitive advantage.

Tariff Impact on Supply Chains and Pricing

Recent US tariff measures are reshaping global sourcing strategies for neurodegenerative drugs, increasing production costs due to higher import duties on raw materials and manufacturing equipment. Companies are exploring domestic production and free-trade zone strategies to mitigate these pressures. Concurrently, value-based procurement models are intersecting with tariff-driven cost changes, underscoring the importance of resilient supply chains and proactive trade management for sustainable competitiveness.

Methodology & Data Sources

This analysis integrates qualitative interviews with industry executives, clinical and market access specialists, together with secondary research from peer-reviewed publications, regulatory filings, and financial reports. Data triangulation and advisory panel reviews ensure rigor, up-to-date insights, and highly actionable market intelligence.

Why This Report Matters

  • Enables strategic decision-makers to anticipate trends, allocate resources, and adapt portfolios to fast-evolving therapeutic and regional landscapes.
  • Provides granular segmentation and regulatory analysis, supporting the optimization of clinical development and commercialization strategies.
  • Empowers organizations to navigate major supply chain or policy disruptions, and harness data-driven approaches to maximize patient impact and market share.

Conclusion

The neurodegenerative drugs market is characterized by dynamic innovation, regulatory evolution, and global demographic shifts. Informed, agile strategies will be essential for success as the market continues to advance and diversify.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Development of multi-target drugs for comprehensive neurodegeneration treatment
5.2. Advancements in gene therapy for treatment of inherited neurodegenerative disorders
5.3. Increasing focus on repurposing existing drugs for neurodegenerative disease applications
5.4. Clinical trial breakthroughs revealing efficacy of novel neurodegenerative therapies
5.5. Integration of AI and machine learning in neurodegenerative drug discovery and development
5.6. Expansion of small molecule drugs targeting neuroinflammation pathways
5.7. Growing impact of immunotherapy approaches in neurodegenerative disease management
5.8. Progress in blood-brain barrier penetration technologies for neurodegenerative drugs
5.9. Emerging role of biomarkers in personalized neurodegenerative drug development
5.10. Innovative drug formulations targeting protein aggregation in neurodegenerative diseases
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Neurodegenerative Drugs Market, by Type
8.1. Introduction
8.2. Branded
8.3. Generics
9. Neurodegenerative Drugs Market, by Drug Class
9.1. Introduction
9.2. Cholinesterase Inhibitors
9.2.1. Donepezil
9.2.2. Pyridostigmine
9.2.3. Rivastigmine
9.3. Decarboxylase Inhibitors
9.3.1. Benserazide
9.3.2. Carbidopa
9.3.3. Methyldopa
9.4. Dopamine Agonist
9.4.1. Apomorphine
9.4.2. Cabergoline
9.4.3. Pramipexole
9.4.4. Rotigotine
9.5. Immunomodulators
10. Neurodegenerative Drugs Market, by Mode Of Administration
10.1. Introduction
10.2. Injectable
10.3. Oral
10.4. Transdermal Patch
11. Neurodegenerative Drugs Market, by Mechanism Of Action
11.1. Introduction
11.2. Ion Channel Modulators
11.2.1. Potassium Channel Modulators
11.2.2. Sodium Channel Modulators
11.3. Synaptic Modulators
12. Neurodegenerative Drugs Market, by Therapeutic Approach
12.1. Introduction
12.2. Neuroprotection
12.2.1. Anti-Inflammatory Agents
12.2.2. Antioxidants
12.3. Preventive Treatment
12.4. Symptomatic Treatment
13. Neurodegenerative Drugs Market, by Indication
13.1. Introduction
13.2. Alzheimer's Disease
13.3. Amyotrophic Lateral Sclerosis (ALS)
13.4. Multiple Sclerosis
13.4.1. Primary Progressive
13.4.2. Relapsing-Remitting
13.5. Parkinson's Disease
14. Neurodegenerative Drugs Market, by Patient Demographics
14.1. Introduction
14.2. Adult
14.3. Geriatric
14.4. Pediatric
15. Neurodegenerative Drugs Market, by Sales Channel
15.1. Introduction
15.2. Offline
15.2.1. Hospitals Pharmacies
15.2.2. Retail Pharmacies
15.3. Online
16. Neurodegenerative Drugs Market, by End User
16.1. Introduction
16.2. Clinics
16.3. Contract Research Organizations
16.4. Hospitals
16.5. Research Institutes
17. Americas Neurodegenerative Drugs Market
17.1. Introduction
17.2. United States
17.3. Canada
17.4. Mexico
17.5. Brazil
17.6. Argentina
18. Europe, Middle East & Africa Neurodegenerative Drugs Market
18.1. Introduction
18.2. United Kingdom
18.3. Germany
18.4. France
18.5. Russia
18.6. Italy
18.7. Spain
18.8. United Arab Emirates
18.9. Saudi Arabia
18.10. South Africa
18.11. Denmark
18.12. Netherlands
18.13. Qatar
18.14. Finland
18.15. Sweden
18.16. Nigeria
18.17. Egypt
18.18. Turkey
18.19. Israel
18.20. Norway
18.21. Poland
18.22. Switzerland
19. Asia-Pacific Neurodegenerative Drugs Market
19.1. Introduction
19.2. China
19.3. India
19.4. Japan
19.5. Australia
19.6. South Korea
19.7. Indonesia
19.8. Thailand
19.9. Philippines
19.10. Malaysia
19.11. Singapore
19.12. Vietnam
19.13. Taiwan
20. Competitive Landscape
20.1. Market Share Analysis, 2024
20.2. FPNV Positioning Matrix, 2024
20.3. Competitive Analysis
20.3.1. Abbott Laboratories
20.3.2. AbbVie Inc.
20.3.3. ACADIA Pharmaceuticals Inc.
20.3.4. Alpha Cognition Inc.
20.3.5. Amneal Pharmaceuticals, Inc.
20.3.6. Aquinnah Pharmaceuticals Inc.
20.3.7. Asceneuron SA
20.3.8. AstraZeneca PLC
20.3.9. AZTherapies, Inc.
20.3.10. Bausch Health Companies Inc.
20.3.11. Biogen Inc.
20.3.12. Boehringer Ingelheim International GmbH
20.3.13. Denali Therapeutics Inc.
20.3.14. Eli Lilly and Company
20.3.15. GlaxoSmithKline PLC
20.3.16. H. Lundbeck A/S
20.3.17. Johnson & Johnson Services, Inc.
20.3.18. Kyowa Kirin International plc
20.3.19. Lupin Limited
20.3.20. Merck & Co., Inc.
20.3.21. Novartis AG
20.3.22. Orion Corporation by Smiths Group plc
20.3.23. Pfizer, Inc.
20.3.24. Sanofi SA
20.3.25. Takeda Pharmaceutical Company Limited
20.3.26. Theravance Biopharma
20.3.27. UCB S.A.
21. ResearchAI
22. ResearchStatistics
23. ResearchContacts
24. ResearchArticles
25. Appendix
List of Figures
FIGURE 1. NEURODEGENERATIVE DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2024 VS 2030 (%)
FIGURE 20. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 22. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. NEURODEGENERATIVE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. NEURODEGENERATIVE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 33. NEURODEGENERATIVE DRUGS MARKET: RESEARCHAI
FIGURE 34. NEURODEGENERATIVE DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 35. NEURODEGENERATIVE DRUGS MARKET: RESEARCHCONTACTS
FIGURE 36. NEURODEGENERATIVE DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. NEURODEGENERATIVE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GENERICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GENERICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DONEPEZIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PYRIDOSTIGMINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PYRIDOSTIGMINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BENSERAZIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BENSERAZIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CARBIDOPA, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CARBIDOPA, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY METHYLDOPA, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY METHYLDOPA, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY APOMORPHINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY APOMORPHINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CABERGOLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CABERGOLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRAMIPEXOLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRAMIPEXOLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ROTIGOTINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ROTIGOTINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY POTASSIUM CHANNEL MODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY POTASSIUM CHANNEL MODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SODIUM CHANNEL MODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SODIUM CHANNEL MODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYNAPTIC MODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYNAPTIC MODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTIOXIDANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTIOXIDANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYMPTOMATIC TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYMPTOMATIC TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS (ALS), BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS (ALS), BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRIMARY PROGRESSIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRIMARY PROGRESSIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RELAPSING-REMITTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RELAPSING-REMITTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 199. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 200. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 201. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 202. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 203. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 204. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 205. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 206. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 207. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2024 (USD MILLION)
TABLE 208. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2025-2030 (USD MILLION)
TABLE 209. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 210. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 211. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 212. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 213. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2024 (USD MILLION)
TABLE 214. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2025-2030 (USD MILLION)
TABLE 215. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
TABLE 216. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
TABLE 217. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2024 (USD MILLION)
TABLE 218. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2025-2030 (USD MILLION)
TABLE 219. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 220. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 221. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
TABLE 222. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2030 (USD MILLION)
TABLE 223. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 224. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 225. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 228. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 229. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 232. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 233. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 234. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 235. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 236. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 237. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 238. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 239. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2024 (USD MILLION)
TABLE 240. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2025-2030 (USD MILLION)
TABLE 241. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 242. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 243. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 244. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 245. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2024 (USD MILLION)
TABLE 246. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2025-2030 (USD MILLION)
TABLE 247. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
TABLE 248. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
TABLE 249. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2024 (USD MILLION)
TABLE 250. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2025-2030 (USD MILLION)
TABLE 251. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 252. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 253. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
TABLE 254. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2030 (USD MILLION)
TABLE 255. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 256. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 257. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 260. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 261. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 264. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 265. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 266. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 267. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 268. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 269. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 270. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 271. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2024 (USD MILLION)
TABLE 272. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2025-2030 (USD MILLION)
TABLE 273. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 274. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 275. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 276. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 277. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2024 (USD MILLION)
TABLE 278. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2025-2030 (USD MILLION)
TABLE 279. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
TABLE 280. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
TABLE 281. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2024 (USD MILLION)
TABLE 282. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2025-2030 (USD MILLION)
TABLE 283. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 284. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 285. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
TABLE 286. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2030 (USD MILLION)
TABLE 287. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 288. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 289. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 290. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 291. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 292. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 293. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 294. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 295. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 296. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 297. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 298. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 299. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 300. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 301. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 302. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 303. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2024 (USD MILLION)
TABLE 304. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2025-2030 (USD MILLION)
TABLE 305. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 306. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 307. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 308. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 309. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2024 (USD MILLION)
TABLE 310. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2025-2030 (USD MILLION)
TABLE 311. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
TABLE 312. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
TABLE 313. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2024 (USD MILLION)
TABLE 314. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2025-2030 (USD MILLION)
TABLE 315. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 316. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 317. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
TABLE 318. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Neurodegenerative Drugs market report include:
  • Abbott Laboratories
  • AbbVie Inc.
  • ACADIA Pharmaceuticals Inc.
  • Alpha Cognition Inc.
  • Amneal Pharmaceuticals, Inc.
  • Aquinnah Pharmaceuticals Inc.
  • Asceneuron SA
  • AstraZeneca PLC
  • AZTherapies, Inc.
  • Bausch Health Companies Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Denali Therapeutics Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin International plc
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Corporation by Smiths Group plc
  • Pfizer, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Theravance Biopharma
  • UCB S.A.

Table Information

Report AttributeDetails
No. of Pages183
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 47.79 Billion
Forecasted Market Value ( USD ) by 2030 $ 69.3 Billion
Compound Annual Growth Rate7.6%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Neurodegenerative Drugs - Global Strategic Business Report - Product Image

Neurodegenerative Drugs - Global Strategic Business Report

  • Report
  • 376 Pages
  • Global
From
Neurodegenerative Diseases Drugs Market Report and Forecast 2025-2034 - Product Image

Neurodegenerative Diseases Drugs Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Neurodegenerative Diseases Therapeutics - Global Strategic Business Report - Product Image

Neurodegenerative Diseases Therapeutics - Global Strategic Business Report

  • Report
  • 387 Pages
  • Global
From
Neurodegenerative Diseases Market by Disease Type, Treatment Type, Treatment Stage, Route of Administration, End User - Global Forecast to 2030 - Product Image

Neurodegenerative Diseases Market by Disease Type, Treatment Type, Treatment Stage, Route of Administration, End User - Global Forecast to 2030

  • Report
  • 199 Pages
  • Global
From
Neurodegenerative Disorder Therapeutics Market Report 2025 - Product Image

Neurodegenerative Disorder Therapeutics Market Report 2025

  • Report
  • 250 Pages
  • Global
From

About the Market

The Neurodegenerative Disease Drug market is a subset of the Central Nervous System Drugs market, which focuses on treatments for diseases that cause the progressive loss of structure or function of neurons, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). These drugs are typically used to slow the progression of the disease, improve symptoms, and improve quality of life. Common treatments include cholinesterase inhibitors, glutamate antagonists, and dopamine agonists. The Neurodegenerative Disease Drug market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Pfizer, Novartis, Merck, Sanofi, and Johnson & Johnson. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.